3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
491
Rectal Neoplasms
267
Colonic Neoplasms
218
Pancreatic Neoplasms
186
Stomach Neoplasms
181
Esophageal Neoplasms
134
Breast Neoplasms
118
Neoplasm Metastasis
116
Squamous Cell Carcinoma of Head and Neck
94
Head and Neck Neoplasms
92
Neoplasms
88
Adenocarcinoma Of Esophagus
67
Esophageal Squamous Cell Carcinoma
61
Carcinoma, Hepatocellular
54
Adenocarcinoma
40
Nasopharyngeal Carcinoma
33
Cholangiocarcinoma
32
Biliary Tract Neoplasms
26
Anus Neoplasms
26
Gastrointestinal Neoplasms
25
Carcinoma, Squamous Cell
25
Carcinoma, Non-Small-Cell Lung
25
Keratosis, Actinic
22
Gallbladder Neoplasms
21
Urinary Bladder Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
20
Liver Neoplasms
20
Bile Duct Neoplasms
19
Ovarian Neoplasms
16
Carcinoma
16
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Standard of Care
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
testosterone 17 beta-cypionate
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Valsartan
1
Urinary Diversion
1
Tranexamic Acid
1
Testosterone Propionate
1
Sunitinib
1
Stents
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Methyltestosterone
1
Immune Checkpoint Inhibitors
1
Ice
1
Hydroxychloroquine
1
Health Information Exchange
1
Gemcitabine
1
Gels
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urologic Diseases
×
Fluorouracil
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled